CONTEXT: Nonalcoholic fatty liver disease and elevated circulating branched-chain amino acids (BCAAs) are common characteristics of obesity and type 2 diabetes. In rodents, brain insulin signaling controls both hepatic triglyceride secretion and BCAA catabolism. Whether brain insulin signaling controls similar metabolic pathways in humans is unknown. OBJECTIVE: Here we assessed if intranasal insulin, a method to preferentially deliver insulin to the central nervous system, is able to modulate hepatic lipid content and plasma BCAAs in humans. DESIGN/ SETTING: We conducted a randomized, double-blind, placebo-controlled trial at the Medical University of Vienna. PARTICIPANTS/INTERVENTION: We assessed if a chronic 4-week intranasal insulin treatment (40 IU, 4 times daily) reduces hepatic triglyceride content and circulating BCAAs in 20 healthy male volunteers. MAIN OUTCOME MEASURES: Hepatic lipid content was assessed noninvasively by 1H-magnetic resonance spectroscopy, and BCAAs were measured by gas chromatography mass spectrometry at defined time points during the study. RESULTS: Chronic intranasal insulin treatment did not alter body weight, body mass index, and hepatic lipid content but reduced circulating BCAA levels. CONCLUSIONS: These findings support the notion that brain insulin controls BCAA metabolism in humans. Thus, brain insulin resistance could account at least in part for the elevated BCAA levels observed in the insulin-resistant state.
CONTEXT: Nonalcoholic fatty liver disease and elevated circulating branched-chain amino acids (BCAAs) are common characteristics of obesity and type 2 diabetes. In rodents, brain insulin signaling controls both hepatic triglyceride secretion and BCAA catabolism. Whether brain insulin signaling controls similar metabolic pathways in humans is unknown. OBJECTIVE: Here we assessed if intranasal insulin, a method to preferentially deliver insulin to the central nervous system, is able to modulate hepatic lipid content and plasma BCAAs in humans. DESIGN/ SETTING: We conducted a randomized, double-blind, placebo-controlled trial at the Medical University of Vienna. PARTICIPANTS/INTERVENTION: We assessed if a chronic 4-week intranasal insulin treatment (40 IU, 4 times daily) reduces hepatic triglyceride content and circulating BCAAs in 20 healthy male volunteers. MAIN OUTCOME MEASURES: Hepatic lipid content was assessed noninvasively by 1H-magnetic resonance spectroscopy, and BCAAs were measured by gas chromatography mass spectrometry at defined time points during the study. RESULTS: Chronic intranasal insulin treatment did not alter body weight, body mass index, and hepatic lipid content but reduced circulating BCAA levels. CONCLUSIONS: These findings support the notion that brain insulin controls BCAA metabolism in humans. Thus, brain insulin resistance could account at least in part for the elevated BCAA levels observed in the insulin-resistant state.
Authors: Otto Tschritter; Hubert Preissl; Anita M Hennige; Michael Stumvoll; Katarina Porubska; Rebekka Frost; Hannah Marx; Benjamin Klösel; Werner Lutzenberger; Niels Birbaumer; Hans-Ulrich Häring; Andreas Fritsche Journal: Proc Natl Acad Sci U S A Date: 2006-07-28 Impact factor: 11.205
Authors: Martin Heni; Robert Wagner; Stephanie Kullmann; Ralf Veit; Haliza Mat Husin; Katarzyna Linder; Charlotte Benkendorff; Andreas Peter; Norbert Stefan; Hans-Ulrich Häring; Hubert Preissl; Andreas Fritsche Journal: Diabetes Date: 2014-07-15 Impact factor: 9.461
Authors: Andrew C Shin; Martin Fasshauer; Nika Filatova; Linus A Grundell; Elizabeth Zielinski; Jian-Ying Zhou; Thomas Scherer; Claudia Lindtner; Phillip J White; Amanda L Lapworth; Olga Ilkayeva; Uwe Knippschild; Anna M Wolf; Ludger Scheja; Kevin L Grove; Richard D Smith; Wei-Jun Qian; Christopher J Lynch; Christopher B Newgard; Christoph Buettner Journal: Cell Metab Date: 2014-10-09 Impact factor: 27.287
Authors: Sulin Cheng; Petri Wiklund; Reija Autio; Ronald Borra; Xiaowei Ojanen; Leiting Xu; Timo Törmäkangas; Markku Alen Journal: PLoS One Date: 2015-10-06 Impact factor: 3.240
Authors: Sofiya Gancheva; Alessandra Bierwagen; Daniel F Markgraf; Gidon J Bönhof; Kevin G Murphy; Erifili Hatziagelaki; Jesper Lundbom; Dan Ziegler; Michael Roden Journal: Mol Metab Date: 2017-10-25 Impact factor: 7.422